Press releases
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
- Soligenix Announces Pricing of $4.75 Million Public Offering
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
- Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
- Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 4.80 |
Average volume | -- |
---|---|
Shares outstanding | 14.24m |
Free float | 14.23m |
P/E (TTM) | -- |
Market cap | 5.91m USD |
EPS (TTM) | -0.9164 USD |
Data delayed at least 15 minutes, as of Feb 15 2023.
More ▼